Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 7/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 7/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 7/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | GCGR | P47871 | 5/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | FYN | P06241 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67820 | 0.90 | MAPK13 (0.67) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL69405 | 0.86 | BRAF (0.44) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL13693260 | 0.85 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL69591 | 0.85 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL67192 | 0.85 | MAPK11 (0.64) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL67132 | 0.84 | FYN (0.44) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL67121 | 0.84 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL69636 | 0.84 | BRAF (0.52) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL69049 | 0.84 | PIK3CG (0.52) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL13693370 | 0.83 | BRAF (0.51) | MAPK14MAPK13MAPK12MAPK11MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015686-A | Novel heterocyclic compounds and uses therof | NOVARTIS AG | 2011-04-13 | — | — | CN | claimed |
| EP-2274300-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | Novartis AG (CH) | 2011-01-19 | — | — | EP | claimed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | claimed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | claimed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| CN-102015686-B | Novel heterocyclic compounds and uses therof | NOVARTIS AG | 2014-07-02 | — | — | CN | disclosed |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | NOVARTIS AG (CH) | 2013-08-15 | — | — | US | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| CN-102015686-A | Novel heterocyclic compounds and uses therof | NOVARTIS AG | 2011-04-13 | — | — | CN | disclosed |
| EP-2274300-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | Novartis AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
| WO-2009115572-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | MAPK14 484/4885MAPK13 178/4885MAPK12 501/4885 |
| US-20130210818-A1 | Novel Heterocyclic Compounds and Uses Thereof | BRAF, RAF1, HRAS | MAPK14 218/4885MAPK13 197/4885MAPK12 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.